Media

Ariceum Therapeutics’ targeted radiopharmaceutical 177Lu-satoreotide exhibits promising clinical response and good tolerability profile in patients with advanced neuroendocrine tumours

Oncopeptides opts to abandon Type II variation process for Pepaxti to optimize patient and shareholder value

Oncopeptides announces successful price negotiations for Pepaxti in Germany

HelloBetter Raises €5 Million to Secure Road to Profitability

Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oncopeptides – CHMP issues positive opinion on Type II variation to extend the therapeutic indication of Pepaxti based on OCEAN trial results

Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer

Oncopeptides publishes two articles with results from ANCHOR and LIGHTHOUSE studies in Haematologica

Oncorena’s First Patient Treated with ONC175 (orellanine) in clinial phase I/II trial  in Patients with Metastatic Renal Cancer and Dialysis at Karolinska University Hospital in Stockholm, Sweden